Observational cohort of liver cancer patients in France
Prospective Cohort of Patients With Hepatocellular Carcinoma in France
This study is collecting information from liver cancer patients in France to better understand how the disease progresses and how different treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Trial ID | NCT04348838 on ClinicalTrials.gov |
What this trial studies
This study aims to collect and analyze data from patients diagnosed with hepatocellular carcinoma (HCC) in France. It focuses on understanding the disease's progression, treatment responses, and outcomes by gathering information from new and existing cases of HCC across multiple centers. The project seeks to address the challenges associated with HCC, including late diagnosis and the need for improved diagnostic and therapeutic strategies. By creating a comprehensive database, the study hopes to enhance knowledge and facilitate future research in this area.
Who should consider this trial
Good fit: Ideal candidates include individuals with new or suspected cases of hepatocellular carcinoma, regardless of the cause or stage of the disease.
Not a fit: Patients with serious life-threatening conditions unrelated to liver disease or those in vulnerable populations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment options for patients with hepatocellular carcinoma.
How similar studies have performed: Other studies focusing on cohort data collection for liver cancer have shown promise in improving understanding and treatment, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New cases of HCC * suspected case of HCC regardless of the cause, stage, treatment * Known HCC: drug treatment for recurrence or progression Exclusion Criteria: * Associated serious condition threatening life in the short term (with the exception of liver disease itself) * So-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision
Where this trial is running
Amiens
- CHU Amiens — Amiens, France (Recruiting)
Study contacts
- Principal investigator: Jean-Claude BARBARE, Pr — CHU Amiens
- Study coordinator: Olivier Ganry, Pr
- Email: ganry.olivier@chu-amiens.fr
- Phone: (33)322668193
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.